

AngioDynamics Highlights Studies Presented at 23rd Annual American College of Phlebology Congress

VenaCure EVLT™, ClosureFAST™ found to have similar efficacy, low pain and bruising

QUEENSBURY, N.Y. November 24, 2009 — [AngioDynamics](#) (NASDAQ : ANGO) announced today that Dr. Lowell Kabnick presented three studies demonstrating the efficacy of the VenaCure EVLT laser system for the treatment of varicose veins at the American College of Phlebology's 23rd Annual Congress in Palm Desert, California.

Dr. Kabnick is Director of the New York University Vein Center and Associate Professor of Surgery in the Division of Vascular Surgery at NYU Medical Center . He also serves as a paid consultant to AngioDynamics. His results included:

- AngioDynamics' NeverTouch® jacket-tip laser fiber is superior in terms of low pain and bruising compared to a bare tip laser fiber,
- The VenaCure EVLT system with the NeverTouch™ jacket laser fiber is similar to Covidien's ClosureFAST radiofrequency system in terms of efficacy, and lack of pain and bruising,
- Laser vein ablation with a VenaCure EVLT system and NeverTouch fiber has a shallower coagulation zone than radiofrequency ablation, which Dr. Kabnick suggests may be helpful for doctors seeking to avoid nerve damage.

“The innovation inherent in our VenaCure EVLT system and the benefits delivered to patients are clearly indicated in these studies,” said Shawn McCarthy, Senior Vice President and General Manager of the Company's Peripheral Vascular Business Unit . “As the leader in laser vein ablation, AngioDynamics is committed to ongoing clinical research that demonstrates VenaCure EVLT's value to physicians and efficacy to their patients.”

In a presentation titled “Laser vs. Radiofrequency for Endothermal Venous Ablation of the GSV: Are the Recovery Results Similar?” Dr. Kabnick presented two studies. The first was a randomized single-site study of 20 patients comparing treatments with a bare-tip laser fiber against the newer jacket-tip NeverTouch fiber. The NeverTouch fiber is a proprietary laser fiber with a gold tip that maximizes tip visibility under ultrasound and eliminates any chance of inadvertent fiber tip contact with the vein wall for improved safety and patient comfort. Analogue pain scores were recorded by patients each day of the first seven days following treatment on a standardized scale from zero to 10. The bare-tip group reported an average score of 1.87 whereas the jacket-tip group reported an average score of 0.76. Analysis and development of the bruising score showed an average of 1.45 for the bare-tip group and 1.05 – translating to less bruising – for the jacket-tip group.

In the second single-site study, 35 patients received treatment for their varicose veins with the VenaCure EVLT system using a NeverTouch fiber and 50 received treatment with ClosureFAST. The results for the two groups were similar in terms of efficacy and lack of pain and bruising. Using the same scale as the previous study, the average bruising score for ClosureFAST was 1.34 and 1.21 for VenaCure EVLT. Average pain was rated 0.8 for ClosureFAST and 0.9 for VenaCure EVLT.

In a second presentation titled “In-Vitro Comparison of Coagulation Zones Using 810nm, 980nm, 1320nm, 1470nm Lasers and Radiofrequency,” Dr. Kabnick presented a model to measure the impacts of power and energy from multiple laser devices including the VenaCure EVLT system and from a radiofrequency device on tissue in an effort to measure depth of coagulation. In the study – drawing a laser fiber and a radiofrequency catheter through a cylinder of bovine tissue encasing a lumen injected with difibrinated blood – the radiofrequency device always generated a more than 5mm coagulation zone. The power and wavelength of the energy emitted by the laser fiber could be calibrated to generate a shallower coagulation zone.

Dr. Kabnick suggested a shallower coagulation zone may produce benefits in terms of nerve sparing and that the ability to change the energy level on a laser fiber may allow for optimization of treatment for different vein diameters.

The Congress was held November 5 through November 8.

About AngioDynamics

AngioDynamics is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency and irreversible electroporation ablation systems , vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.AngioDynamics.com .

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "affirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "potential," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect actual results include, without limitation, the ability of AngioDynamics to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to execute its leadership development plan and integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2009. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.